TEVA reports Wednesday morning with its short positioning at a three-month low and options traders showing little conviction either way. Short interest fell 14% over the past month to 26.7 million shares. Cost to borrow remains trivial at under 0.5%, and utilisation sits at just 1.68% — well off the 52-week high of 12.68%. The positioning suggests shorts have largely vacated ahead of the print. The stock fell 5.4% this week to close at $30.64, giving back some of the 5.1% gain posted over the past month. Put/call ratio ticked up to 0.49, slightly above its 20-day average but still well below the 52-week high of 0.76. Options positioning is muted rather than defensive.
Analyst activity has clustered around the mid-$40s this quarter. BofA lifted its target from $38 to $42 in early April while holding Buy. Goldman raised to $45 in February. Barclays, Truist and Piper Sandler all moved targets into the $38-$42 range after the January print. The Street sees upside driven by Ajovy and Uzedy growth — the two specialty products are expected to post 17% and 45% year-over-year gains respectively by year-end. Bulls point to $700 million in anticipated cost savings and expanding EBITDA margins as cash flow accelerates into 2027. Bears flag sequential revenue pressure in the first quarter from inventory dynamics, pricing headwinds ahead of IRA implementation, and an expected downturn in Austedo sales next year despite near-term strength. The generics division missed expectations by 3% last quarter on falling US prescriptions. Regulatory uncertainty around tariffs and Most-Favored-Nation policy adds another layer of risk.
Institutional holders have been largely stable. Top Israeli funds Migdal and Phoenix collectively hold over 10% of shares outstanding. WCM Investment Management nearly doubled its position in the first quarter, adding 13.8 million shares to bring its stake to 14 million. Insider activity has been modest — EVP Mark Sabag sold $1.87 million worth of shares in mid-March, but net insider activity over the past 90 days shows buying of roughly 209,000 shares worth $6.6 million. After the January earnings call, the stock rallied 1.7% the next day and 7.5% over the following week.
The print will test whether management can thread the needle on guidance — delivering specialty growth and margin expansion while absorbing the generics headwinds and pricing pressure the Street already expects. ORTEX short score stands at 34, reflecting the relatively light short positioning heading into the release.
See the live data behind this article on ORTEX.
Open TEVA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
